Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

88.51
-2.2100-2.44%
Pre-market: 89.010.5000+0.56%08:43 EDT
Volume:2.23M
Turnover:197.92M
Market Cap:5.34B
PE:-188.32
High:91.70
Open:90.73
Low:86.90
Close:90.72
52wk High:109.28
52wk Low:36.88
Shares:60.34M
Float Shares:39.99M
Volume Ratio:2.62
T/O Rate:5.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.4700
ROE:-8.65%
ROA:-1.83%
PB:16.97
PE(LYR):-188.32

Loading ...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 11, 2025

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
Dec 10, 2025

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Dec 10, 2025

Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says

MT Newswires Live
·
Dec 10, 2025

Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Dec 09, 2025

Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating

MT Newswires Live
·
Dec 09, 2025

Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug

Reuters
·
Dec 08, 2025

Mirum Pharma Exec Says No Change to 2025 Forecast

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharma CEO Says Addition of Brelovitug to Pipeline Will Bring Revenue Potential of Rare Disease Portfolio to Over $4 Bln - Conf Call

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharma Exec Says Co Expects to Return to Cash Flow Positive in 2027

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharma Exec Expects Brelovitug Global Sales Potential of at Least $750 Mln

THOMSON REUTERS
·
Dec 08, 2025

BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics

Reuters
·
Dec 08, 2025

Mirum Pharmaceuticals Enters Into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: Brelovitug Being Evaluated in Azure Phase 3 Registrational Program for Hdv

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: Entered Into Definitive Agreement With Syndicate of Healthcare Investors for a Private Placement

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: Deal Approved by Boards of Both Cos and Expected to Close in Q1 2026

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: Private Placement Expected to Close Concurrently With Acquisition & Result in Gross Proceeds to Co of About $200 Mln

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: Azure Phase 3 Program Currently Enrolling Patients, With Top-Line Data Expected in 2H 2026 With Bla Submission, Launch in 2027

THOMSON REUTERS
·
Dec 08, 2025

Mirum Pharmaceuticals: to Buy Bluejay for $250 Mln in Cash, $370 Mln in Co's Common Stock & Sales-Based Milestone Payments of Upto $200 Mln in Cash

THOMSON REUTERS
·
Dec 08, 2025

Director Michael G. Grey reports disposal of common shares of Mirum Pharmaceuticals Inc

Reuters
·
Dec 03, 2025